Literature DB >> 28681270

Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality.

Maddalena Alessandra Wu1, Federica Leidi2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28681270     DOI: 10.1007/s11739-017-1710-0

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  5 in total

1.  European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.

Authors:  S B Debast; M P Bauer; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2014-03       Impact factor: 8.067

Review 2.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

3.  Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.

Authors:  Vanessa W Stevens; Richard E Nelson; Elyse M Schwab-Daugherty; Karim Khader; Makoto M Jones; Kevin A Brown; Tom Greene; Lindsay D Croft; Melinda Neuhauser; Peter Glassman; Matthew Bidwell Goetz; Matthew H Samore; Michael A Rubin
Journal:  JAMA Intern Med       Date:  2017-04-01       Impact factor: 21.873

4.  Recurrent Clostridium difficile infection is associated with increased mortality.

Authors:  M A Olsen; Y Yan; K A Reske; M D Zilberberg; E R Dubberke
Journal:  Clin Microbiol Infect       Date:  2014-10-12       Impact factor: 8.067

5.  All-cause mortality in hospitalized patients with infectious diarrhea: Clostridium difficile versus other enteric pathogens in Austria from 2008 to 2010.

Authors:  D Schmid; H W Kuo; E Simons; E E Kanitz; J Wenisch; F Allerberger; C Wenisch
Journal:  J Infect Public Health       Date:  2013-11-11       Impact factor: 3.718

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.